JP6387389B2 - 小児充実性腫瘍の処置の方法 - Google Patents

小児充実性腫瘍の処置の方法 Download PDF

Info

Publication number
JP6387389B2
JP6387389B2 JP2016500995A JP2016500995A JP6387389B2 JP 6387389 B2 JP6387389 B2 JP 6387389B2 JP 2016500995 A JP2016500995 A JP 2016500995A JP 2016500995 A JP2016500995 A JP 2016500995A JP 6387389 B2 JP6387389 B2 JP 6387389B2
Authority
JP
Japan
Prior art keywords
individual
taxane
less
composition
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016500995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512513A5 (enrdf_load_stackoverflow
JP2016512513A (ja
Inventor
ブーシュラ ブネテーブ，
ブーシュラ ブネテーブ，
イリアーナ エリアス，
イリアーナ エリアス，
マルクス レンシュラー，
マルクス レンシュラー，
ニール ピー． デサイ，
ニール ピー． デサイ，
Original Assignee
アブラクシス バイオサイエンス， エルエルシー
アブラクシス バイオサイエンス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブラクシス バイオサイエンス， エルエルシー, アブラクシス バイオサイエンス， エルエルシー filed Critical アブラクシス バイオサイエンス， エルエルシー
Publication of JP2016512513A publication Critical patent/JP2016512513A/ja
Publication of JP2016512513A5 publication Critical patent/JP2016512513A5/ja
Application granted granted Critical
Publication of JP6387389B2 publication Critical patent/JP6387389B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
JP2016500995A 2013-03-13 2014-03-10 小児充実性腫瘍の処置の方法 Active JP6387389B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361780658P 2013-03-13 2013-03-13
US61/780,658 2013-03-13
US201361805817P 2013-03-27 2013-03-27
US61/805,817 2013-03-27
US201361829940P 2013-05-31 2013-05-31
US61/829,940 2013-05-31
US201361909868P 2013-11-27 2013-11-27
US61/909,868 2013-11-27
PCT/US2014/022541 WO2014143613A1 (en) 2013-03-13 2014-03-10 Methods of treatment of pediatric solid tumor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018009402A Division JP2018062528A (ja) 2013-03-13 2018-01-24 小児充実性腫瘍の処置の方法

Publications (3)

Publication Number Publication Date
JP2016512513A JP2016512513A (ja) 2016-04-28
JP2016512513A5 JP2016512513A5 (enrdf_load_stackoverflow) 2017-04-06
JP6387389B2 true JP6387389B2 (ja) 2018-09-05

Family

ID=51537501

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016500995A Active JP6387389B2 (ja) 2013-03-13 2014-03-10 小児充実性腫瘍の処置の方法
JP2018009402A Withdrawn JP2018062528A (ja) 2013-03-13 2018-01-24 小児充実性腫瘍の処置の方法
JP2019124315A Pending JP2019163334A (ja) 2013-03-13 2019-07-03 小児充実性腫瘍の処置の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018009402A Withdrawn JP2018062528A (ja) 2013-03-13 2018-01-24 小児充実性腫瘍の処置の方法
JP2019124315A Pending JP2019163334A (ja) 2013-03-13 2019-07-03 小児充実性腫瘍の処置の方法

Country Status (12)

Country Link
US (1) US20160015817A1 (enrdf_load_stackoverflow)
EP (1) EP2968253A4 (enrdf_load_stackoverflow)
JP (3) JP6387389B2 (enrdf_load_stackoverflow)
KR (1) KR20150126671A (enrdf_load_stackoverflow)
CN (1) CN105209035A (enrdf_load_stackoverflow)
AU (2) AU2014228386B2 (enrdf_load_stackoverflow)
CA (1) CA2903470A1 (enrdf_load_stackoverflow)
HK (1) HK1219231A1 (enrdf_load_stackoverflow)
IL (1) IL240987A0 (enrdf_load_stackoverflow)
MX (1) MX2015011783A (enrdf_load_stackoverflow)
NZ (1) NZ630367A (enrdf_load_stackoverflow)
WO (1) WO2014143613A1 (enrdf_load_stackoverflow)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
EP2117520B1 (en) 2006-12-14 2018-08-29 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
SG175239A1 (en) 2009-04-15 2011-11-28 Abraxis Bioscience Llc Prion-free nanoparticle compositions and methods
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
CA3087813A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of treating cancer
SG186112A1 (en) 2010-06-04 2013-01-30 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
KR101970342B1 (ko) 2011-04-28 2019-04-18 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
SI2790675T1 (sl) 2011-12-14 2019-11-29 Abraxis Bioscience Llc Uporaba polimernih pomožnih snovi za liofilizacijo ali zamrzovanje delcev
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
KR102191311B1 (ko) 2013-03-12 2020-12-15 아브락시스 바이오사이언스, 엘엘씨 폐암의 치료 방법
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
CN108024999A (zh) 2015-06-29 2018-05-11 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
RU2020134124A (ru) 2018-03-20 2022-04-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ
AU2020375810A1 (en) 2019-10-28 2022-05-12 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
CN1101700C (zh) * 1997-12-05 2003-02-19 上海众联生化技术开发有限公司 多肽口服液
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
EP2359859A1 (en) 2002-12-09 2011-08-24 Abraxis BioScience, LLC Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents
CN1261161C (zh) * 2003-11-10 2006-06-28 钱汶光 复方干扰素诱生剂口含片
MX2007009960A (es) 2005-02-18 2008-03-11 Abraxis Bioscience Inc Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
NZ566705A (en) 2005-08-31 2011-06-30 Abraxis Bioscience Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
CA2686736A1 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension
JP2013511549A (ja) * 2009-11-20 2013-04-04 インフィニティー ファーマシューティカルズ， インコーポレイテッド ヘッジホッグ関連癌の治療のための方法及び組成物
KR20130028727A (ko) * 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
WO2011153009A1 (en) * 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer

Also Published As

Publication number Publication date
JP2019163334A (ja) 2019-09-26
JP2018062528A (ja) 2018-04-19
KR20150126671A (ko) 2015-11-12
CA2903470A1 (en) 2014-09-18
EP2968253A4 (en) 2016-11-02
WO2014143613A1 (en) 2014-09-18
CN105209035A (zh) 2015-12-30
US20160015817A1 (en) 2016-01-21
AU2014228386A1 (en) 2015-09-24
MX2015011783A (es) 2015-12-01
AU2019201357A1 (en) 2019-03-21
AU2014228386B2 (en) 2018-11-29
NZ630367A (en) 2017-02-24
JP2016512513A (ja) 2016-04-28
EP2968253A1 (en) 2016-01-20
HK1219231A1 (zh) 2017-03-31
IL240987A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
JP6387389B2 (ja) 小児充実性腫瘍の処置の方法
TWI495467B (zh) 肝細胞癌之治療方法
JP6257324B2 (ja) 膵臓がんの処置方法
JP5579057B2 (ja) 再発性癌の処置のための方法および組成物
JP6342918B2 (ja) 膵臓がんの処置方法
JP6513467B2 (ja) 治療薬の組み合わせおよび投与の様式ならびに併用療法
AU2010224012B2 (en) Combination therapy with thiocolchicine derivatives
RU2678448C2 (ru) Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента
KR20170101925A (ko) 병용 요법
JP2016175947A (ja) 増殖性疾患を処置するための組み合わせ療法
JP2019529520A (ja) 胆道がんを処置する方法
HK1165957A (en) Combination therapy with thiocolchicine derivatives
HK1165957B (en) Combination therapy with thiocolchicine derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180711

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180813

R150 Certificate of patent or registration of utility model

Ref document number: 6387389

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250